RENO, Nev., Sept. 17, 2012 /PRNewswire/ -- Lifeline
Biotechnologies, Inc. (OTC Market: LLBO) announces the award of US
Patent #8,231,542 B2 for System For Analyzing Thermal Data Based
on Breast Surface Temperature to Determine Suspect
Conditions.
Jim Holmes, Lifeline's CEO
said, "This System patent completes our group of three software
patents. We now have our Methods, Device and System patents
which provide the Company with protection of its developed
technology. Methods for Collecting and Analyzing Thermal Data
Based on Breast Surface Temperature to Determine Suspect
Conditions; Device For Analyzing Thermal Data Based On
Breast Surface Temperature For Detection For Use In Determining
Cancerous Conditions; and, System For Analyzing Thermal Data
Based On Breast Surface Temperature To Determine Suspect
Conditions."
First Warning Systems, Lifeline Biotechnologies' exclusive
licensee, is currently updating the patient data collection device
and its interpretive software, covered by these patents, to
complete the product package in preparation for market entry.
First Warning is conducting a funding round. Company
information is being posted on GUST (an association of angel
investors who are accredited and qualified).
About First Warning Systems
First Warning Systems, (FWS) founded in 2008, is based in
Reno, NV. FWS' principal
shareholder is Lifeline Biotechnologies, Inc. Lifeline has
licensed (includes a revenue royalty feature) FWS with the
worldwide exclusive right for development, manufacturing,
marketing and commercialization of its intellectual property.
The product is a device and process that detects breast
tissue abnormalities. Many of these tissue abnormalities will
develop into breast diseases, some of which will be breast cancers.
The FWS process does not involve compression or radiation and
is noninvasive. Three clinical trials with over 650 participants
have achieved proof of concept and superior outcomes when compared
to other protocols. FWS is planning a final, limited clinical
trial and a 510k device classification to validate the fourth
generation of the FWS product. FWS is preparing to apply for a Euro
CE Mark to market in the UK, EU and Russian markets. See FWS'
video, "Breast Cancer Tumor Progression" at
www.firstwarningsystems.com.
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded
in 1994 is based in Reno,
NV. LLBO has invested over $10M
in a device and process for early detection of breast tissue
abnormalities some of which are cancerous or pre-cancer.
Three "Proof of Concept" clinical trials of over 650 women have
been completed and four patents (one hardware, three software) have
been awarded. www.lbti.com. Lifeline's efforts continue to have DTC
remove the chill and allow trading to resume.
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
For more information, contact: Jim Holmes, CEO
775-852-3222 Email:
Jholmes@lbti.com
SOURCE Lifeline Biotechnologies, Inc.